CMMB News and Press, Chemomab Therapeutics Ltd.

TEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor and other members of its s...

— New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a P hase 3 Registration Trial — TEL AVIV, Israel, Dec. 02, 2025 (GLOB...

2025-11-20 08:33:46 ET More on Chemomab Therapeutics Seeking Alpha’s Quant Rating on Chemomab Therapeutics Historical earnings data for Chemomab Therapeutics Financial information for Chemomab Therapeutics Read the full article on Seeking Alpha ...

—Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment Advances, with EMA Guidance Supporting a Single Nebokitug Phase 3 Registration Trial Using a Clinical Event Composite Endpoint — —Phase 2 S...

GRI Bio Inc. (GRI) is expected to report $-1.11 for Q3 2025 Meridian Mining UK Societas (MRRDF) is expected to report $-0.01 for Q3 2025 CaliberCos Inc. (CWD) is expected to report $-0.32 for Q3 2025 BioCorRx Inc (BICX) is expected to report $-0.06 for Q3 2025 Beneficient (BENF) i...

— Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks— —New Clinical Data Provides Insights on Nebokitug’s Direct Macrophage-Mediated M...

2025-08-26 09:42:44 ET DENVER, Colo., Aug 26, 2025 ( 247marketnews.com )- Biotechs are lighting up the tape. Allarity Therapeutics (NASDAQ:ALLR) is charging ahead after announcing FDA Fast Track designation for its dual PARP/WNT inhibitor stenoparib in advanced ovarian cancer. T...

Chemomab Therapeutics Ltd. (CMMB) is expected to report $-0.2 for Q2 2025

— Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Executing the Nebokitug Phase 3 Program— —Phase 2 SPRING Trial Data Highlighting Nebokitug’s Unique Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects ...

SPRING Trial Data Presented at BSG Live’25 Confirms the Clinical Potential of Nebokitug as a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3 Treatment with Nebokitug Is Well-Tolerated and Associated with Substantial Improvements in Multiple Fibrot...